{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:53:49Z","timestamp":1784238829428,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009530","name":"Jawaharlal Institute Of Postgraduate Medical Education and Research","doi-asserted-by":"publisher","award":["JIP\/Res\/Intramural\/phs 2 and 3\/2021-22"],"award-info":[{"award-number":["JIP\/Res\/Intramural\/phs 2 and 3\/2021-22"]}],"id":[{"id":"10.13039\/501100009530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009530","name":"Jawaharlal Institute Of Postgraduate Medical Education and Research","doi-asserted-by":"publisher","award":["JIP\/Res\/Intramural\/phs 2 and 3\/2021-22"],"award-info":[{"award-number":["JIP\/Res\/Intramural\/phs 2 and 3\/2021-22"]}],"id":[{"id":"10.13039\/501100009530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014825","name":"Biotechnology Industry Research Assistance Council","doi-asserted-by":"publisher","award":["BIRAC\/BT\/NBM0252\/05\/19"],"award-info":[{"award-number":["BIRAC\/BT\/NBM0252\/05\/19"]}],"id":[{"id":"10.13039\/501100014825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014825","name":"Biotechnology Industry Research Assistance Council","doi-asserted-by":"publisher","award":["BIRAC\/BT\/NBM0252\/05\/19"],"award-info":[{"award-number":["BIRAC\/BT\/NBM0252\/05\/19"]}],"id":[{"id":"10.13039\/501100014825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014825","name":"Biotechnology Industry Research Assistance Council","doi-asserted-by":"publisher","award":["BIRAC\/BT\/NBM0252\/05\/19"],"award-info":[{"award-number":["BIRAC\/BT\/NBM0252\/05\/19"]}],"id":[{"id":"10.13039\/501100014825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02655-y","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T21:26:49Z","timestamp":1742419609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Addition of thalidomide for prevention of chemotherapy-induced nausea and vomiting in the second cycle after the failure of four-drug regimen in the first cycle"],"prefix":"10.1007","volume":"42","author":[{"given":"Nishil","family":"Gowda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirunalini","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyaselvi","family":"Indrajithu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamizharasan","family":"Paninathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"2655_CR1","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. New England J Med. 2016;375:1395\u20136.","journal-title":"New England J Med"},{"key":"2655_CR2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncol. 2015;20:576\u201383.","journal-title":"Oncol"},{"key":"2655_CR3","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782\u201397.","journal-title":"J Clin Oncol"},{"key":"2655_CR4","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.20.00871","volume":"38","author":"RD Naik","year":"2020","unstructured":"Naik RD, et al. Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial. J Clin Oncol. 2020;38:3785\u201393.","journal-title":"J Clin Oncol"},{"key":"2655_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30001","author":"P Patel","year":"2022","unstructured":"Patel P, Robinson PD, Cohen M, et al. prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: a clinical practice guideline. Pediat Blood Cancer. 2022. https:\/\/doi.org\/10.1002\/pbc.30001.","journal-title":"Pediat Blood Cancer"},{"key":"2655_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac240","author":"R Navari","year":"2023","unstructured":"Navari R, Binder G, et al. Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of recurrent CINV in later cycles. Oncol. 2023. https:\/\/doi.org\/10.1093\/oncolo\/oyac240.","journal-title":"Oncol"},{"key":"2655_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00913","author":"GJ Sanger","year":"2018","unstructured":"Sanger GJ, Andrews PLR. A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Front Pharmacol. 2018. https:\/\/doi.org\/10.3389\/fphar.2018.00913.","journal-title":"Front Pharmacol"},{"key":"2655_CR8","doi-asserted-by":"crossref","first-page":"100138","DOI":"10.1016\/j.crphar.2022.100138","volume":"3","author":"PLR Andrews","year":"2022","unstructured":"Andrews PLR, Williams RSB, Sanger GJ. Anti-emetic effects of thalidomide: evidence, mechanism of action, and future directions. Current Res Pharmacol Drug Discov. 2022;3:100138.","journal-title":"Current Res Pharmacol Drug Discov"},{"key":"2655_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.818839","author":"J Xie","year":"2022","unstructured":"Xie J, Zhang C, Li S, et al. Efficacy and safety of thalidomide as a pre-medication of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC): a systematic review and meta-analysis. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2021.818839.","journal-title":"Front Oncol"},{"key":"2655_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.818839","author":"J Xie","year":"2017","unstructured":"Xie J, Zhang C, Li S, Dai R, et al. Efficacy of thalidomide in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: a randomized, multicenter, double-blind, placebo-controlled phase III trial (CLOG1302 study). J Clin Oncol. 2017. https:\/\/doi.org\/10.3389\/fonc.2021.818839.","journal-title":"J Clin Oncol"},{"key":"2655_CR11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"2655_CR12","unstructured":"Fayers P, Aaronson NK, Bjordal K, et al: The EORTC QLQ-C30 Scoring Manual (3rd Edition). European organisation for research and treatment of cancer, Brussels 2001"},{"key":"2655_CR13","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.7150\/jca.45678","volume":"11","author":"N Wang","year":"2020","unstructured":"Wang N, Peng X, Liu Y, et al. Efficacy and safety of thalidomide for chemotherapy-induced nausea and vomiting. J Cancer. 2020;11:4560\u201370.","journal-title":"J Cancer"},{"issue":"3","key":"2655_CR14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12160-014-9670-3","volume":"49","author":"VF Quinn","year":"2024","unstructured":"Quinn VF, Colagiuri B. Placebo interventions for nausea: a systematic review. Ann Behav Med. 2024;49(3):449\u201362.","journal-title":"Ann Behav Med"},{"key":"2655_CR15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cac2.12397","volume":"43","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhao B, Chen G, et al. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer Commun (London, England). 2023;43:246\u201356.","journal-title":"Cancer Commun (London, England)"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02655-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:29:53Z","timestamp":1743380993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02655-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2655"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02655-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the Institutional Ethics Committee, JIPMER, (no: JIP\/IEC\/2021\/038).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients enrolled in this trial provided written informed consent using a form which was approved by the Institutional Ethics Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"121"}}